BioCentury
ARTICLE | Company News

Clinuvel, Retrophin deal

August 11, 2014 7:00 AM UTC

Clinuvel rejected an unsolicited July proposal from Retrophin to acquire Clinuvel in either a cash or stock deal. The cash deal values Clinuvel at A$92.2 million ($85.6 million) and the stock deal val...